Docetaxel / E-cadherin Cancer Research Results

docx, Docetaxel: Click to Expand ⟱
Features:
Docetaxel, (brand name Taxotere) is a chemotherapy medication used to treat breast cancer, head and neck cancer, stomach cancer, prostate cancer and non-small-cell lung cancer.
Docetaxel is a microtubule-stabilizing agent (taxane). It binds β-tubulin and promotes microtubule polymerization / prevents depolymerization, causing mitotic arrest (G2/M) and downstream cell death.
Clinically important constraints:
-Neutropenia / febrile neutropenia are major dose-limiting toxicities.
-Premedication with dexamethasone is standard to reduce fluid retention and hypersensitivity reactions.
-Metabolism is mainly CYP3A4, so strong CYP3A4 inhibitors/inducers (and grapefruit) can materially change exposure.


Rank Pathway / Axis Cancer / Tumor Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 Microtubule stabilization (β-tubulin) → mitotic spindle dysfunction Microtubule dynamics ↓; mitotic progression fails Also impacts normal proliferating cells P, R Core cytotoxic mechanism Taxane class MOA: stabilizes microtubules and blocks depolymerization, disrupting mitosis.
2 Mitotic arrest (G2/M checkpoint pressure) G2/M arrest ↑; proliferation ↓ Bone marrow / GI epithelium vulnerability ↑ R, G Cell-cycle blockade Mitotic arrest is the key phenotype linking microtubule disruption to cell death outcomes.
3 Intrinsic apoptosis (mitochondrial) secondary to mitotic catastrophe Apoptosis ↑ (context); caspase activation ↑ ↔ / tissue injury possible at high exposure G Death execution Cell death often occurs after prolonged mitotic arrest (mitotic catastrophe → apoptosis).
4 Neutropenia / marrow suppression (on-target toxicity) — Neutrophils ↓; febrile neutropenia risk ↑ R, G Dose-limiting toxicity Major clinical constraint; risk increases with dose and interacting drugs.
5 Hypersensitivity reactions — Hypersensitivity risk ↑ (especially early infusions) P, R Acute infusion risk Premedication is used to reduce frequency/severity of hypersensitivity reactions.
6 Fluid retention / capillary leak tendency — Fluid retention ↑ (can be severe) R, G Key non-hematologic toxicity Dexamethasone premedication is standard to reduce incidence and severity.
7 Combination leverage (sensitization with other agents) Synergy reported in multiple regimens Toxicity may ↑ depending on partner drug G Regimen-driven efficacy Docetaxel is commonly used in multi-agent protocols; outcome is regimen- and tumor-type-specific.
8 Pharmacokinetics (CYP3A4 metabolism) Exposure ↑ with strong CYP3A4 inhibitors; ↓ with inducers Exposure shifts → toxicity/efficacy shifts P, R Interaction driver Docetaxel is primarily cleared by CYP3A4; strong inhibitors can raise levels substantially.
9 Grapefruit / intestinal CYP3A4 inhibition (interaction risk) Potential exposure ↑ (context) Potential toxicity ↑ (context) P, R Diet–drug interaction Grapefruit can inhibit intestinal CYP3A4; docetaxel is a CYP3A4 substrate, so avoidance is commonly advised.
10 Parameter dependence (dose/schedule; weekly vs q3wk) Mechanism constant; tolerability differs by schedule Toxicity profile differs by schedule — Translation constraint Clinical outcomes and toxicity balance are schedule-dependent (protocol-specific).
11 ROS generation (secondary to mitotic stress) ROS ↑ (mitochondrial); lipid peroxidation ↑ (reported) Oxidative injury possible R, G Stress amplification ROS increase is secondary to mitotic arrest and mitochondrial dysfunction, not a primary redox drug effect.
12 NRF2 antioxidant response NRF2 ↑ (adaptive; reported in resistant models) Protective antioxidant upshift R, G Resistance mechanism NRF2 activation may reduce docetaxel sensitivity by increasing antioxidant capacity (GSH, NQO1, HO-1).

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (binding and immediate microtubule dynamic suppression begins)
  • R: 30 min–3 hr (mitotic checkpoint engagement; acute infusion effects)
  • G: >3 hr (mitotic catastrophe, apoptosis, tissue-level toxicities)
E-cadherin, E-cadherin: Click to Expand ⟱
Source: HalifaxProj(restore)
Type:
Also known as Cadherin1 (CDH1)
E-cadherin, is a type of cell adhesion molecule that plays a crucial role in maintaining tissue structure and cell-cell interactions. In the context of cancer, E-cadherin has been found to be a tumor suppressor gene.

E-cadherin is a transmembrane protein that mediates cell-cell adhesion through its extracellular domain, which interacts with other E-cadherin molecules on adjacent cells. This interaction helps to maintain tissue integrity and prevent cancer cells from invading surrounding tissues.

In many types of cancer, including breast, colon, and prostate cancer, E-cadherin expression is often reduced or lost.
cell adhesion molecules spanning four families of 1) Integrins (α2β1, α5/β1, αL/β2); 2) Cadherins (E-cad, P-cad, N-cad); 3) Ig-CAMs (VCAM, NCAM, ICAM, Nectins, Necl); and 4) Selectins (E-selectin, P-selectin, L-selectin).
Scientific Papers found: Click to Expand⟱
96- QC,  docx,    Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways
- vitro+vivo, Pca, LNCaP - in-vitro, Pca, PC3
PI3K/Akt↓, Ki-67↓, BAX↑, Bcl-2↓, EpCAM↓, Twist↓, E-cadherin↑, P-gp↓, TumCP↓, TumCMig↓, TumCI↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis ⓘ

PI3K/Akt↓, 1,  

Cell Death ⓘ

BAX↑, 1,   Bcl-2↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

EpCAM↓, 1,  

Migration ⓘ

E-cadherin↑, 1,   Ki-67↓, 1,   TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 1,   Twist↓, 1,  

Barriers & Transport ⓘ

P-gp↓, 1,  

Clinical Biomarkers ⓘ

Ki-67↓, 1,  
Total Targets: 12

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: E-cadherin, E-cadherin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:178  Target#:89  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page